Table 3.
Studies testing the relationship between IGF-1 and mortality
| Author Year Ref | Time of follow up (years) | Number and age of Subjects | Results |
|---|---|---|---|
| Pros | |||
| Brugts MP (2008) ref 40 |
8,6 yr | 376 men age: 73–94 yr |
There is positive relationship between IGF-I bioactivity and survival in older male subjects. Negative relationship between IGF-I bioactivity and cardiovascular risk. |
| Cappola AR (2003) ref 42 |
5 yr | 718 women age >65 yr (77,6 yr) |
The combination of low IGF-I and high IL-6 levels confers a high risk for progressive disability and death in women. |
| Friedrich N (2009) ref 38 |
8,5 yr | 1988 men 2069 women age 20–79 yr |
No association between IGF-I levels and mortality in women. In men an inverse associations between IGF-I levels and all cause mortality, cardiovascular mortality or cancer death. |
| Roubenoff R (2003) ref 35 |
4 yr | 525 subjects 202 men 323 women age 72–92 |
Low IGF-I levels is associated with increased mortality in community-dwelling elderly adults. The relationship remains significant after adjustment for multiple confounders. |
| Arai Y (2008) ref 36 |
6,2 yr | 252 subjects 197 women 55 men age > 100 yr |
The IGF-I axis may be potentially important for maintaining health and function and promoting survival at an extremely old age. The relationship between low IGF-I levels and mortality remains significant after adjusting for multiple confounders. When adjusted for covariates and for conventional risk factors, like serum levels of albumin, HDL-C, and IL-6 the relationship loses significance. |
| Laughlin GA (2004) ref 39 |
13 yr | 633 men 552 women 51–98 yr |
Low IGF-I levels are predictors of mortality for all causes and for non-ischemic heart disease (IHD) cardiovascular mortality. Negative correlation between IGF-I levels and mortality for ischemic heart disease in men and women, independent of cardiovascular risk factors. |
| Saydah S (2007) ref 37 |
12 yr | 6056 subjects 2741 men 3315 women age 43,9 yr |
Mortality decreased with increasing IGF-I quartiles for deaths from all causes, heart disease and cancer but the trend was not statistically significant for adjusted models. |
| Yamaguchi H (2008) ref 41 |
90 days | 54 patients with acute myocardial infarction | Low concentration of serum IGF-I on admission was associated with a poor early prognosis of acute myocardial infarction. |
| Cons | |||
| Andreassen M (2009) ref 43 |
30 months | 363 subjects: 194 cases 169 controls (105 women, 258 men) age 68 ±10 |
IGF-I levels were not reduced in patients with CHF and did not influence cardiac status at baseline or the prognosis |
| Hu D (2009) ref 44 |
6,2 yr | 625 subjects: age > 70 yr |
No association between IGF-I levels and all cause mortality |
| Kaplan R (2008) ref 45 |
8 yr | 1122 subjects: 725 women 397 men age >65 yr |
Low total IGF-I had a marginal association with weaker hand-grip strength, but total IGF-I levels did not predict walking speed, incident decline in functional status or mortality. |
| Raynaud Simon (2001) ref 46 |
6 yr | 256 subjects age 65–101 yr |
Highest IGF-I levels were associated with higher risk of short term mortality |
| Andreassen (2009) ref 47 |
5 yr (median) | 642 men and women 50–89 68.3±10.8 years |
High IGF-I levels were independently associated with increased all cause mortality and risk of development of CHF |
| Major J (2010) ref 48 |
18 yr | 633 men age>50 yr (mean 73) |
Higher serum IGF-I in older men is associated with increased risk cancer of death |